Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$4.6M
Filings
42
Firms Hired
2
Active Period
2017–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft); H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft); H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 841
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft); H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
2022 · third_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Client expense: — · Firm income: $70,000
Matched citations: H.R. 841
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Client expense: — · Firm income: $70,000
Matched citations: S. 4348
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
2022 · second_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Client expense: — · Firm income: $80,000
Matched citations: H.R. 841
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; S. 4348, FDASLA Act of 2022; The Cannabis Administration and Opportunity Act (discussion draft).
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
2022 · first_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Client expense: — · Firm income: $80,000
Matched citations: H.R. 841
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
2021 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Client expense: — · Firm income: $90,000
Matched citations: H.R. 841
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
2021 · third_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; The Cannabis Administration and Opportunity Act (discussion draft).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 841
SAFE Banking Act of 2021
2021 · second_quarter · Firm: GREENWICH BIOSCIENCES, INC.
S.910 SAFE Banking: Issues related to the definition of business of insurance
Client expense: $280,000 · Firm income: —
Matched citations: S.910
SAFE Banking Act of 2021
2021 · second_quarter · Firm: GREENWICH BIOSCIENCES, INC.
S.910 SAFE Banking: Issues related to the definition of business of insurance
Client expense: $270,000 · Firm income: —
Matched citations: S.910
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
2021 · second_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids; H.R. 841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021
Client expense: — · Firm income: $60,000
Matched citations: H.R. 841
Medical Marijuana Research Act
2020 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids, including H.R. 3797, The Medical Marijuana Research Act of 2019.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3797
Medical Marijuana Research Act
2020 · third_quarter · Firm: COVINGTON & BURLING LLP
Education and support for public policies related to the research and development of, and access to, FDA-approved therapies containing CBD or other cannabinoids, including H.R. 3797, The Medical Marijuana Research Act of 2019.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3797
HR 171; HR 601; HR 3797; HR2843; HR 3884, S2032 - Marijuana Research Bills
Client expense: $240,000 · Firm income: —
Matched citations: HR 171
Marijuana Freedom and Opportunity Act
2020 · first_quarter · Firm: GREENWICH BIOSCIENCES, INC.
HR 171; HR 601; HR 3797; HR2843; HR 3884, S2032 - Marijuana Research Bills
Client expense: $240,000 · Firm income: —
Matched citations: HR2843
Medical Marijuana Research Act
2020 · first_quarter · Firm: GREENWICH BIOSCIENCES, INC.
HR 171; HR 601; HR 3797; HR2843; HR 3884, S2032 - Marijuana Research Bills
Client expense: $240,000 · Firm income: —
Matched citations: HR 3797
HR 171; HR 601; HR 3797; HR2843; HR 3884, S2032 - Marijuana Research Bills
Client expense: $240,000 · Firm income: —
Matched citations: HR 3884
Medical Cannabis Research Act of 2019
2020 · first_quarter · Firm: GREENWICH BIOSCIENCES, INC.
HR 171; HR 601; HR 3797; HR2843; HR 3884, S2032 - Marijuana Research Bills
Client expense: $240,000 · Firm income: —
Matched citations: HR 601
Cannabidiol and Marihuana Research Expansion Act
2020 · first_quarter · Firm: GREENWICH BIOSCIENCES, INC.
HR 171; HR 601; HR 3797; HR2843; HR 3884, S2032 - Marijuana Research Bills
Client expense: $240,000 · Firm income: —
Matched citations: S2032
SAFE Banking Act of 2019
2019 · fourth_quarter · Firm: GREENWICH BIOSCIENCES, INC.
HR 1595 - Secure and Fair Enforcement Banking Act of 2019 or the SAFE Banking Act of 2019
Client expense: $250,000 · Firm income: —
Matched citations: HR 1595
SAFE Banking Act of 2019
2019 · fourth_quarter · Firm: GREENWICH BIOSCIENCES, INC.
HR 1595 - Secure and Fair Enforcement Banking Act of 2019 or the SAFE Banking Act of 2019
Client expense: $250,000 · Firm income: —
Matched citations: HR 1595
The STATES Act (S. 3032/H.R. 6043) - Issues related to the FDA - Regulations to implement 2018 Farm Bill Provisions; 2019 Consolidated Appropriations Act - Sections 536 & 537's impact on other agencies; HR 3055 - Clarifying agency roles around Food, Drug and Cosmetic Act; HR1595 - Clarifying proposed definitions; Regulation of cannabis based medicines
Client expense: $390,000 · Firm income: —
Matched citations: H.R. 6043
SAFE Banking Act of 2019
2019 · third_quarter · Firm: GREENWICH BIOSCIENCES, INC.
The STATES Act (S. 3032/H.R. 6043) - Issues related to the FDA - Regulations to implement 2018 Farm Bill Provisions; 2019 Consolidated Appropriations Act - Sections 536 & 537's impact on other agencies; HR 3055 - Clarifying agency roles around Food, Drug and Cosmetic Act; HR1595 - Clarifying proposed definitions; Regulation of cannabis based medicines
Client expense: $390,000 · Firm income: —
Matched citations: HR1595
Source: Senate LDA